ERBB2 and breast cancer: The proportion of HR+ in HER2-negative tumors (1156, 84.8%) was much higher than that in HR− tumors (207, 15.2%), and HR+ (320, 81.0%) tumors was more common than HR− (75, 19.0%) in HER2 ultra-low BC patients.